Polyurethane Construction Adhesive

SECTION 2: Hazards identification

OSHA Please note that as a service to our customers, hazard warnings and information have been included for ALL chemicals listed in this MSDS. However, not all of these chemicals are

Most important adverse effects

EYE: Direct contact irritates moderately with redness and swelling. Calcium carbonate, xylene, calcium oxide, and MDI may cause severe eye irritation, especially in dust form. Butyl benzyl phthalate (BBP) may cause irritation with symptoms of redness and itching. SKIN: A single short exposure (less than 24 hours) may irritate. Repeated prolonged contact (24 to 48 hours) may irritate moderately. Product contains calcium carbonate, xylene, and calcium oxide, which are possible skin sensitizers. Contact with BBP may cause irritation with symptoms of redness and itching. MDI may cause irritation to the skin or mucous membranes. Ethyl benzene may be absorbed through the skin. INHALATION: Vapor overexposure, and/or inhalation of silica or calcium oxide dust may severely irritate eyes, nose, throat, upper respiratory tract, and lungs. Vapor overexposure may cause drowsiness. Excessive inhalation of calcium carbonate (dust form) may result in shortness of breath or reduced pulmonary function. Inhalation of high concentrations of BBP, xylene, or ethyl benzene may cause respiratory irritation or difficulties and central nervous system effects characterized by headache, nausea, dizziness, and/or drowsiness. MDI vapors or mist can cause irritation of upper respiratory tract: signs/symptoms can include soreness of the nose and throat, coughing, and sneezing. Persons previously sensitized to isocyanates may experience an allergic respiratory reaction: signs/symptoms can include difficulty breathing, wheezing, tightness of chest, and respiratory failure. Overexposure to titanium dioxide (dust form) may cause pulmonary fibrosis (scarring of the lungs). ORAL: Small amounts transferred to the mouth by fingers during use, etc. should not injure. Swallowing large amounts may cause digestive discomfort and gastrointestinal irritation. Ingestion of BBP may cause central nervous system depression with symptoms seen in acute inhalation. Ingestion of xylene may cause central nervous system effects. Aspiration of xylene or ethyl benzene into lungs may cause chemical pneumonitis. SECTION III - HAZARDOUS INGREDIENTS/IDENTITY INFORMATION This product consists of a mixture/preparation. CAS INGREDIENT WT LETHAL DOSES EXPOSURE LIMITS NO. % TWA STEL Ceiling 3 ppm mg/m 3 ppm mg/m 3 ppm mg/m 85-68-7 Butyl Benzyl Phthalate 15-40 Inhalation TCLo – OSHA No exposure limit guidelines have been established (BBP) 789 mg/m3/6hr (rat) for this material. Oral LD50 – NIOSH 2,330 mg/kg (rat) Dermal LD50 – ACGIH 6,700 mg/kg (rat) CANADA a 1317-65- Calcium Carbonate 3-7 Oral LD50 – b OSHA - 15, 5 - 3 (Limestone) 7,340 mg/kg (rat) NIOSH - 10, 5 b - ACGIH - 10 - b CANADA - 10, 5 - a 1305-78- Calcium Oxide 1-5 Not established OSHA - 5 - 8 c NIOSH - 2 - ACGIH - 2 - CANADA - 2 - 4 - a 13463- Titanium dioxide 1-5 Inhalation TCLo – d OSHA - 15 - 67-7 250 mg/m3/6hr (rat) Oral LD50 – NIOSH e - >24,000 mg/kg (rat) Dermal LD50 – ACGIH - 10 - >10,000 mg/m3 CANADA - 10, 5 b - (rabbit) 1330-20- Xylene 1-5 Inhalation LC50 – OSHA 100 435 - 7 5,000 ppm/4hr (rat) CAS INGREDIENT WT LETHAL DOSES EXPOSURE LIMITS NO. % TWA STEL Ceiling 3 ppm mg/m 3 ppm mg/m 3 ppm mg/m Oral LD50 – NIOSH 100 435 150 655 - 4,300 mg/kg (rat) Dermal LD50 – f ACGIH 100 434 150 651 - >1,700 mg/kg CANADA 100 434 150 652 - (rabbit) 101-68-8 Diphenylmethane 0.5- Inhalation LC50 – OSHA - 0.02 0.2 diisocyanate (MDI) 1.5 178 mg/m3 (rat) g NIOSH 0.005 0.050 - 0.020 0.2 Oral LD50 – ACGIH 0.005 0.051 - 2,200 mg/kg CANAD (mouse) A 0.005 0.051 - 0.02 0.2 100-41-4 Ethyl benzene 0.1- Oral LD50 – 1.0 3,500 mg/kg (rat) OSHA 100 435 - Dermal LD50 – 17,800 µL/kg (rabbit) NIOSH 100 435 125 545 - f Inhalation LCLo – ACGIH 100 434 125 543 - 4,000 ppm/4hr (rat) CANAD A 100 434 125 542 - 14808- a Silica, crystalline < 0.1 Implant TDLo – b, 30, 10 60-7 (Silica, quartz) OSHA - h - 900 mg/kg (rat) NIOSH - 0.5 - Inhalation TCLo – i ACGIH - 0.5 - 300 µg/m3 (human) Intravenous LDLo – CANAD - 0.3, 0.1 - b 40 mg/kg (mouse) A a Under normal conditions of use, no respirable particles should be released from this product. b Total mass; respirable mass, respectively. c NIOSH permissible exposure limits for calcium oxide are as follows: TWA 2 mg/m3; IDLH 25 mg/m3 d OSHA – Total dust. e NIOSH – No threshold has been determined; limit occupational exposure to lowest feasible concentration. f ACGIH – Biological Exposure Index (BEI). g NIOSH – Value based on an exposure time of 10 minutes. h OSHA PEL Silica, Crystalline (Silica, Quartz) – respirable dust TWA 10 mg/m3 divided by %SiO2+2); total dust TWA 30 mg/m3 divided by (%SiO2+2) (Source NIOSH Pocket Guide to Hazardous Chemicals). i Respirable mass. SECTION IV – FIRST-AID PROCEDURES